Availability of HIV treatments contributed to a resurgence in syphilis

A study in Health Economics uncovered an unintended consequence of a major medical breakthrough: while the availability of HIV treatments in the late 1990s dramatically improved survival, they also contributed to a resurgence in syphilis, a sexually transmitted infection.

Through statistical analyses of information from the Centers for Disease Control, as well as pharmaceutical industry sales data, investigators found that US states with higher AIDS prevalence experienced significantly larger increases in syphilis after highly active antiretroviral therapy (HAART) became widely available-with these increases concentrated among men, while rates among women continued to decline-suggesting that changes in sexual behavior following the reduced perceived risk of HIV had broader public health effects.

Data indicated that in the absence of HAART, there would have been 81% fewer syphilis cases between 1996 and 2008.

With syphilis now at a 60‐year high, these findings offer timely insight into how life‐saving innovations can reshape population behavior and highlight the need for complementary public‐health strategies."

David Beheshti, PhD, corresponding author, University of Texas at San Antonio

Source:
Journal reference:

Beheshti, D., et al. (2026). Unintended Consequences of Life‐Saving Pharmaceutical Innovations: How HAART Led to the Resurgence of Syphilis. Health Economics. DOI: 10.1002/hec.70100. https://onlinelibrary.wiley.com/doi/10.1002/hec.70100

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New HIV-seq tool advances understanding of persistent viral reservoirs